Illumina, Inc. ILMN recently introduced its second FDA-regulated and CE-IVD marked next-generation sequencing (NGS) system — NextSeq 550Dx. The instrument has been designed to deliver the power of ...
Both FDA-regulated and CE-in vitro diagnostic (IVD) marked, the NextSeq 550Dx instrument enables clinical laboratories to develop and perform a wide range of applications, from NGS IVD assays using ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Illumina is facing cybersecurity vulnerabilities in some of the next generation sequencing software for its instruments FDA said. The agency released a notice on June 2 about the affected software, ...
SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Roche, a global pioneer in pharmaceuticals and diagnostics, today ...
Illumina has discovered multiple cybersecurity flaws in software embedded in several of its genetic sequencing instruments, potentially opening a door for hackers to access or alter patients’ ...
Illumina now has a solid diagnostic NGS portfolio, courtesy of its NextSeq 550Dx and the MiSeqDx products. This portfolio is capable of meeting any clinical requirement for NGS-based in vitro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results